Literature DB >> 20102450

Postmortem blood concentrations of R- and S-enantiomers of methadone and EDDP in drug users: influence of co-medication and p-glycoprotein genotype.

Anders Buchard1, Kristian Linnet, Sys Stybe Johansen, Julie Munkholm, Michael Fregerslev, Niels Morling.   

Abstract

We investigated toxicological and pharmacogenetic factors that could influence methadone toxicity using postmortem samples. R- and S-methadone were measured in femoral blood from 90 postmortem cases, mainly drug users. The R-enantiomer concentrations significantly exceeded that of the S-enantiomers (Wilcoxon's test, p < 0.001). The samples were divided into four groups according to other drugs detected (methadone only, methadone and strong analgesics, methadone and benzodiazepines, or methadone and other drugs). There was no significant difference in any of the R-methadone/total methadone ratios among the four groups. The median R/S ratio was 1.38, which tends to be higher than that reported for the plasma of living subjects. In addition, we investigated whether small nucleotide polymorphisms in the MDR1 gene that encode the drug transporter P-glycoprotein were associated with the concentrations of R- and S-methadone and its metabolite 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine. No significant association was detected.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20102450     DOI: 10.1111/j.1556-4029.2009.01278.x

Source DB:  PubMed          Journal:  J Forensic Sci        ISSN: 0022-1198            Impact factor:   1.832


  9 in total

1.  Toxicogenetics--cytochrome P450 microarray analysis in forensic cases focusing on morphine/codeine and diazepam.

Authors:  H Andresen; C Augustin; T Streichert
Journal:  Int J Legal Med       Date:  2012-08-17       Impact factor: 2.686

Review 2.  Pharmacogenetics of Opioid Use Disorder Treatment.

Authors:  Richard C Crist; Toni-Kim Clarke; Wade H Berrettini
Journal:  CNS Drugs       Date:  2018-04       Impact factor: 5.749

Review 3.  Transporter-Mediated Disposition of Opioids: Implications for Clinical Drug Interactions.

Authors:  Robert Gharavi; William Hedrich; Hongbing Wang; Hazem E Hassan
Journal:  Pharm Res       Date:  2015-05-14       Impact factor: 4.200

4.  CYP2B6 SNPs are associated with methadone dose required for effective treatment of opioid addiction.

Authors:  Orna Levran; Einat Peles; Sara Hamon; Matthew Randesi; Miriam Adelson; Mary Jeanne Kreek
Journal:  Addict Biol       Date:  2011-07-25       Impact factor: 4.280

5.  Quantification of morphine, morphine 6-glucuronide, buprenorphine, and the enantiomers of methadone by enantioselective mass spectrometric chromatography in whole blood.

Authors:  Dorte J Christoffersen; Charlotte Brasch-Andersen; Jørgen L Thomsen; Martin Worm-Leonhard; Per Damkier; Kim Brøsen
Journal:  Forensic Sci Med Pathol       Date:  2015-03-24       Impact factor: 2.007

6.  Parent and Metabolite Opioid Drug Concentrations in Unintentional Deaths Involving Opioid and Benzodiazepine Combinations.

Authors:  Marcia D Fields; Marie A Abate; Lan Hu; D Leann Long; Matthew L Blommel; Nabila A Haikal; James C Kraner
Journal:  J Forensic Sci       Date:  2015-07       Impact factor: 1.832

7.  ABCB1 gene polymorphisms are associated with fatal intoxications involving venlafaxine but not citalopram.

Authors:  L Karlsson; H Green; A L Zackrisson; F Bengtsson; I Jakobsen Falk; B Carlsson; J Ahlner; F C Kugelberg
Journal:  Int J Legal Med       Date:  2013-03-21       Impact factor: 2.686

8.  The Role of Risk or Contributory Death Factors in Methadone-Related Fatalities: A Review and Pooled Analysis.

Authors:  Arianna Giorgetti; Jennifer Pascali; Massimo Montisci; Irene Amico; Barbara Bonvicini; Paolo Fais; Alessia Viero; Raffaele Giorgetti; Giovanni Cecchetto; Guido Viel
Journal:  Metabolites       Date:  2021-03-22

Review 9.  Chiral Drug Analysis in Forensic Chemistry: An Overview.

Authors:  Cláudia Ribeiro; Cristiana Santos; Valter Gonçalves; Ana Ramos; Carlos Afonso; Maria Elizabeth Tiritan
Journal:  Molecules       Date:  2018-01-28       Impact factor: 4.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.